Francis Lo Sells 79,590 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 79,590 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $17.73, for a total transaction of $1,411,130.70. Following the completion of the sale, the insider owned 315,978 shares in the company, valued at $5,602,289.94. The trade was a 20.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Francis Lo also recently made the following trade(s):

• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total value of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $17.78 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The stock’s 50 day moving average price is $16.54 and its 200 day moving average price is $14.46. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -32.93 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The business had revenue of $93.97 million during the quarter, compared to analyst estimates of $58.76 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The company’s revenue was up 102.4% on a year-over-year basis. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of ADPT. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter worth about $30,000. Smartleaf Asset Management LLC lifted its stake in shares of Adaptive Biotechnologies by 593.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares during the period. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. Quadrant Capital Group LLC bought a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth $133,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth $134,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

ADPT has been the topic of several recent analyst reports. Guggenheim assumed coverage on Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price objective on the stock. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Piper Sandler boosted their target price on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Finally, JPMorgan Chase & Co. increased their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.11.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.